Barclays
TEVA icon

Barclays’s Teva Pharmaceuticals TEVA Stock Holding History

Barclays’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.5M Sell
1,343,554
-57,117
-4% -$1.9M 0.01% 771
2026
Q1 		$42.2M Buy
1,400,671
+5,000
+0.4% +$161K 0.01% 792
2025
Q4 		$43.6M Buy
1,395,671
+720,545
+107% +$17.8M 0.01% 846
2025
Q3 		$13.6M Buy
675,126
+75,112
+13% +$1.32M ﹤0.01% 1450
2025
Q2 		$10.1M Sell
600,014
-163,832
-21% -$2.64M ﹤0.01% 1580
2025
Q1 		$11.7M Buy
763,846
+440,350
+136% +$7.87M ﹤0.01% 1296
2024
Q4 		$7.13M Sell
323,496
-104,099
-24% -$1.89M ﹤0.01% 1845
2024
Q3 		$7.71M Buy
427,595
+102,848
+32% +$1.8M ﹤0.01% 1684
2024
Q2 		$5.28M Sell
324,747
-373,257
-53% -$5.75M ﹤0.01% 1497
2024
Q1 		$9.85M Sell
698,004
-303,177
-30% -$3.82M ﹤0.01% 1399
2023
Q4 		$10.5M Sell
1,001,181
-117,021
-10% -$1.09M ﹤0.01% 1485
2023
Q3 		$11.4M Buy
1,118,202
+69,502
+7% +$647K 0.01% 947
2023
Q2 		$7.9M Sell
1,048,700
-736,245
-41% -$5.97M 0.01% 1088
2023
Q1 		$15.8M Buy
1,784,945
+782,101
+78% +$7.73M 0.01% 958
2022
Q4 		$9.15M Buy
1,002,844
+128,177
+15% +$1.12M ﹤0.01% 1248
2022
Q3 		$7.06M Buy
874,667
+262,338
+43% +$2.32M 0.01% 990
2022
Q2 		$4.6M Buy
612,329
+216,984
+55% +$1.89M ﹤0.01% 1390
2022
Q1 		$3.71M Sell
395,345
-750,574
-65% -$6.26M ﹤0.01% 1413
2021
Q4 		$9.18M Sell
1,145,919
-199,367
-15% -$1.8M ﹤0.01% 1312
2021
Q3 		$13.1M Sell
1,345,286
-74,233
-5% -$695K 0.01% 1053
2021
Q2 		$14.1M Buy
1,419,519
+607,253
+75% +$6.43M 0.01% 1051
2021
Q1 		$9.37M Sell
812,266
-59,505
-7% -$682K 0.01% 1118
2020
Q4 		$8.41M Buy
871,771
+104,286
+14% +$999K ﹤0.01% 1236
2020
Q3 		$6.92M Buy
767,485
+42,394
+6% +$448K ﹤0.01% 1213
2020
Q2 		$8.94M Sell
725,091
-623,149
-46% -$7.05M 0.01% 1034
2020
Q1 		$12.1M Sell
1,348,240
-1,228,884
-48% -$12.6M 0.01% 886
2019
Q4 		$25.3M Buy
2,577,124
+1,403,587
+120% +$12.5M 0.01% 830
2019
Q3 		$8.07M Sell
1,173,537
-371,900
-24% -$2.85M 0.01% 1461
2019
Q2 		$14.3M Buy
1,545,437
+304,293
+25% +$3.67M 0.01% 1128
2019
Q1 		$19.5M Buy
1,241,144
+20,190
+2% +$356K 0.01% 868
2018
Q4 		$18.8M Sell
1,220,954
-152,778
-11% -$3.13M 0.01% 784
2018
Q3 		$29.6M Buy
1,373,732
+288,537
+27% +$6.7M 0.02% 655
2018
Q2 		$26.4M Sell
1,085,195
-186,006
-15% -$3.79M 0.02% 644
2018
Q1 		$21.7M Sell
1,271,201
-1,255,294
-50% -$24.5M 0.02% 807
2017
Q4 		$47.9M Buy
2,526,495
+1,028,094
+69% +$15.5M 0.04% 429
2017
Q3 		$26.4M Buy
1,498,401
+216,317
+17% +$4.87M 0.03% 548
2017
Q2 		$42.6M Sell
1,282,084
-440,865
-26% -$13.6M 0.05% 323
2017
Q1 		$55.3M Buy
1,722,949
+596,713
+53% +$20.4M 0.06% 228
2016
Q4 		$40.8M Buy
1,126,236
+662,482
+143% +$26.5M 0.04% 326
2016
Q3 		$21.3M Sell
463,754
-2,723,181
-85% -$142M 0.02% 525
2016
Q2 		$160M Buy
3,186,935
+2,311,490
+264% +$123M 0.21% 68
2016
Q1 		$46.4M Buy
875,445
+115,072
+15% +$6.75M 0.07% 240
2015
Q4 		$49.4M Sell
760,373
-52,748
-6% -$3.26M 0.06% 283
2015
Q3 		$45.5M Sell
813,121
-103,881
-11% -$6.74M 0.05% 306
2015
Q2 		$54.1M Buy
917,002
+265,226
+41% +$16.4M 0.06% 269
2015
Q1 		$40.4M Sell
651,776
-46,101
-7% -$2.68M 0.05% 391
2014
Q4 		$39.8M Sell
697,877
-762,887
-52% -$42.5M 0.04% 431
2014
Q3 		$77.4M Buy
1,460,764
+208,823
+17% +$11.1M 0.07% 213
2014
Q2 		$65.1M Sell
1,251,941
-702,852
-36% -$35.9M 0.07% 239
2014
Q1 		$102M Buy
1,954,793
+438,332
+29% +$20.3M 0.12% 146
2013
Q4 		$60.7M Buy
1,516,461
+333,728
+28% +$13.1M 0.06% 280
2013
Q3 		$43.8M Buy
1,182,733
+365,119
+45% +$14.2M 0.05% 335
2013
Q2 		$32M Buy
+817,614
New +$31.8M 0.04% 416

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Barclays's TEVA Position: Q2 2026 in Review

Barclays reduced its Teva Pharmaceuticals (TEVA) stake by 4.1% in Q2 2026, selling an estimated $1.9M and leaving 1,343,554 shares worth $45.5M. The position accounts for 0.01% of the portfolio, ranked #771.

Barclays first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $160M in Q2 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Barclays held 1,343,554 shares of Teva Pharmaceuticals worth $45.5M as of Q2 2026.
  • Barclays sold 57,117 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.9M.
  • Teva Pharmaceuticals made up 0.01% of Barclays's portfolio in Q2 2026, its #771 holding.
  • Barclays first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Teva Pharmaceuticals position peaked at $160M in Q2 2016.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.